An open, noncomparative study of amoxapine in borderline disorders.

Abstract

Five patients with borderline personality disorder (BPD) and 5 patients with schizotypal personality disorder (SPD) completed at least 3 weeks of treatment with amoxapine. The patients fulfilled DSM-III criteria for borderline disorders and scored 7 points or more in Gunderson's Diagnostic Interview for Borderlines (DIB). The final median medication in patients with BPD was 200 mg amoxapine/day and 42 mg oxazepam/day. Duration of treatment averaged 28 days. In patients with SPD the corresponding figures were 250 mg amoxapine/day, 36 mg oxazepam/day and 39 days. The study suggests that amoxapine improves schizophrenic-like and depressive symptoms in patients with schizotypal personality disorders (SPD). No effect could be shown in patients with borderline personality disorders (BPD).

• Authors: H V Jensen, J Andersen
• Journal: Acta psychiatrica Scandinavica (Acta Psychiatr Scand) Vol. 79 Issue 1 Pg. 89-93 (Jan 1989) ISSN: 0001-690X [Print] United States
• PMID: 2648768 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Dibenzoxazepines
• Amoxapine

Topics

• Adult
• Amoxapine (therapeutic use)
• Borderline Personality Disorder (drug therapy, psychology)
• Clinical Trials as Topic
• Dibenzoxazepines (therapeutic use)
• Female
• Humans
• Male
• Personality Disorders (drug therapy)
• Psychiatric Status Rating Scales
• Schizotypal Personality Disorder (drug therapy)